Provides access to growth capital and enhanced access to federal projects
DURHAM, N.C., March 14, 2024 (Globe Newswire) — Scorpius Holdings Co., Ltd. (New York Stock Exchange American: SCPX), a integrated contract development and manufacturing organization (CDMO), today announced that it has been approved to join the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), part of the National Biopharmaceutical Manufacturing Partnership. The BioMap consortium has a $20 billion funding cap through which it will not only provide growth capital, but also provide streamlined access to services for government-funded manufacturing programs.
The BioMaP consortium supports the Biomedical Advanced Research and Development Authority (BARDA) and supports the entire pharmaceutical and vaccine manufacturing supply chain, including manufacturers of raw materials and consumables, developers of innovative manufacturing technologies, and suppliers of fill-finish services. Comprised of industry partners across the globe. . The consortium will expand the industrial and manufacturing base for medical countermeasures, including the necessary capabilities, flexibility, and strategies to secure the medical supplies needed to meet the nation's public health preparedness and response requirements. We aim to do so.
“We are honored to be accepted as a member of the BioMaP consortium, which provides Scorpius with an opportunity to support biomanufacturing programs focused on national medical countermeasures programs,” said Jeff Wolf, CEO of Scorpius. “It provides biomanufacturing capabilities and defense capabilities.” “We look forward to building on our track record of supporting infectious disease and biodefense programs on behalf of BARDA, the U.S. Department of Health and Human Services, and the U.S. Department of Defense.”
Scorpius Holdings Co., Ltd.
Scorpius Holdings Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologics and cell therapy programs into the clinic and beyond. Scorpius provides a wide range of analytical testing, process development, and manufacturing services to pharmaceutical and biotechnology companies at our state-of-the-art facility in San Antonio, Texas. With an experienced team and a new, purpose-built facility in the United States, Scorpius is dedicated to transparent collaboration and flexible, high-quality biomanufacturing of biologics. For more information, please visit www.scorpiusbiologics.com.
Forward-looking statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “could,” “continue,” and “continue.” “Similar expressions such as “expect,'' “anticipate,'' “intend,'' “plan,'' “believe,'' “estimate,'' and other similar expressions that focus on national health response programs. Includes a description of our opportunities to support manufacturing programs, etc. On behalf of BARDA, HHS, and the Department of Defense, we support infectious disease and biodefense programs by providing biomanufacturing capabilities and capabilities to protect against pandemics and other emerging threats. Important factors that could cause actual results to differ materially from current expectations include, among other things, our ability to expand our polymer biomanufacturing CDMO services and continue to grow our revenues. our financing needs, our cash balances sufficient to sustain our operations and our ability to raise capital as needed, our ability to utilize fixed costs and achieve long-term profitability; our ability to obtain regulatory approvals or comply with current regulatory requirements, regulatory limitations on our ability to adequately market our services and compete as a pure-play CDMO and our Form 10; -K Other factors described in our annual report for the year ended December 31, 2022, and subsequent quarterly reports on Form 10-Qs and other filings we make with the SEC. The information in this presentation is provided only as of the date hereof and, except as required by law, the Company reserves the right to make any statements regarding the forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise. We undertake no obligation to update the description.
Contact for media and investor information
david waldman
+1 919 289 4017
ir@scorpiusbiologics.com
